200 related articles for article (PubMed ID: 36543146)
1. Genomic heterogeneity as a barrier to precision oncology in urothelial cancer.
Clinton TN; Chen Z; Wise H; Lenis AT; Chavan S; Donoghue MTA; Almassi N; Chu CE; Dason S; Rao P; Rodrigues JA; Vasani NB; Ridouani F; Rosenberg JE; Bajorin DF; Teo MY; Bochner BH; Berger MF; Ostrovnaya I; Pietzak EJ; Iyer G; Gao SP; Hu W; Al-Ahmadie HA; Solit DB
Cell Rep; 2022 Dec; 41(12):111859. PubMed ID: 36543146
[TBL] [Abstract][Full Text] [Related]
2. Genomic profiling of Chinese patients with urothelial carcinoma.
Yang B; Zhao X; Wan C; Ma X; Niu S; Guo A; Wang J; Wang J; Sun D; Jiao S
BMC Cancer; 2021 Feb; 21(1):162. PubMed ID: 33588785
[TBL] [Abstract][Full Text] [Related]
3. Correlation of Somatic Genomic Alterations Between Tissue Genomics and ctDNA Employing Next-Generation Sequencing: Analysis of Lung and Gastrointestinal Cancers.
Toor OM; Ahmed Z; Bahaj W; Boda U; Cummings LS; McNally ME; Kennedy KF; Pluard TJ; Hussain A; Subramanian J; Masood A
Mol Cancer Ther; 2018 May; 17(5):1123-1132. PubMed ID: 29500272
[TBL] [Abstract][Full Text] [Related]
4. Next-generation Sequencing of Nonmuscle Invasive Bladder Cancer Reveals Potential Biomarkers and Rational Therapeutic Targets.
Pietzak EJ; Bagrodia A; Cha EK; Drill EN; Iyer G; Isharwal S; Ostrovnaya I; Baez P; Li Q; Berger MF; Zehir A; Schultz N; Rosenberg JE; Bajorin DF; Dalbagni G; Al-Ahmadie H; Solit DB; Bochner BH
Eur Urol; 2017 Dec; 72(6):952-959. PubMed ID: 28583311
[TBL] [Abstract][Full Text] [Related]
5. Clinical utility of plasma ctDNA sequencing in metastatic urothelial cancer.
Helal C; Pobel C; Bayle A; Vasseur D; Nicotra C; Blanc-Durand F; Naoun N; Bernard-Tessier A; Patrikidou A; Colomba E; Flippot R; Fuerea A; Auger N; Ngo Camus M; Besse B; Lacroix L; Rouleau E; Ponce S; Italiano A; Loriot Y
Eur J Cancer; 2023 Dec; 195():113368. PubMed ID: 37897866
[TBL] [Abstract][Full Text] [Related]
6. Circulating Tumor DNA Reveals Clinically Actionable Somatic Genome of Metastatic Bladder Cancer.
Vandekerkhove G; Todenhöfer T; Annala M; Struss WJ; Wong A; Beja K; Ritch E; Brahmbhatt S; Volik SV; Hennenlotter J; Nykter M; Chi KN; North S; Stenzl A; Collins CC; Eigl BJ; Black PC; Wyatt AW
Clin Cancer Res; 2017 Nov; 23(21):6487-6497. PubMed ID: 28760909
[No Abstract] [Full Text] [Related]
7. Serial monitoring of genomic alterations in circulating tumor cells of ER-positive/HER2-negative advanced breast cancer: feasibility of precision oncology biomarker detection.
Cani AK; Dolce EM; Darga EP; Hu K; Liu CJ; Pierce J; Bradbury K; Kilgour E; Aung K; Schiavon G; Carroll D; Carr TH; Klinowska T; Lindemann J; Marshall G; Rowlands V; Harrington EA; Barrett JC; Sathiyayogan N; Morrow C; Sero V; Armstrong AC; Baird R; Hamilton E; Im SA; Jhaveri K; Patel MR; Dive C; Tomlins SA; Udager AM; Hayes DF; Paoletti C
Mol Oncol; 2022 May; 16(10):1969-1985. PubMed ID: 34866317
[TBL] [Abstract][Full Text] [Related]
8. Targeted DNA and RNA Sequencing of Paired Urothelial and Squamous Bladder Cancers Reveals Discordant Genomic and Transcriptomic Events and Unique Therapeutic Implications.
Hovelson DH; Udager AM; McDaniel AS; Grivas P; Palmbos P; Tamura S; Lazo de la Vega L; Palapattu G; Veeneman B; El-Sawy L; Sadis SE; Morgan TM; Montgomery JS; Weizer AZ; Day KC; Neamati N; Liebert M; Keller ET; Day ML; Mehra R; Tomlins SA
Eur Urol; 2018 Dec; 74(6):741-753. PubMed ID: 30033047
[TBL] [Abstract][Full Text] [Related]
9. Clinical and Genomic Landscape of FGFR3-Altered Urothelial Carcinoma and Treatment Outcomes with Erdafitinib: A Real-World Experience.
Guercio BJ; Sarfaty M; Teo MY; Ratna N; Duzgol C; Funt SA; Lee CH; Aggen DH; Regazzi AM; Chen Z; Lattanzi M; Al-Ahmadie HA; Brannon AR; Shah R; Chu C; Lenis AT; Pietzak E; Bochner BH; Berger MF; Solit DB; Rosenberg JE; Bajorin DF; Iyer G
Clin Cancer Res; 2023 Nov; 29(22):4586-4595. PubMed ID: 37682528
[TBL] [Abstract][Full Text] [Related]
10. Genomic predictors of survival in patients with high-grade urothelial carcinoma of the bladder.
Kim PH; Cha EK; Sfakianos JP; Iyer G; Zabor EC; Scott SN; Ostrovnaya I; Ramirez R; Sun A; Shah R; Yee AM; Reuter VE; Bajorin DF; Rosenberg JE; Schultz N; Berger MF; Al-Ahmadie HA; Solit DB; Bochner BH
Eur Urol; 2015 Feb; 67(2):198-201. PubMed ID: 25092538
[TBL] [Abstract][Full Text] [Related]
11. Next-generation sequencing (NGS) of cell-free circulating tumor DNA and tumor tissue in patients with advanced urothelial cancer: a pilot assessment of concordance.
Barata PC; Koshkin VS; Funchain P; Sohal D; Pritchard A; Klek S; Adamowicz T; Gopalakrishnan D; Garcia J; Rini B; Grivas P
Ann Oncol; 2017 Oct; 28(10):2458-2463. PubMed ID: 28945843
[TBL] [Abstract][Full Text] [Related]
12. High concordance of actionable genomic alterations identified between circulating tumor DNA-based and tissue-based next-generation sequencing testing in advanced non-small cell lung cancer: The Korean Lung Liquid Versus Invasive Biopsy Program.
Park S; Olsen S; Ku BM; Lee MS; Jung HA; Sun JM; Lee SH; Ahn JS; Park K; Choi YL; Ahn MJ
Cancer; 2021 Aug; 127(16):3019-3028. PubMed ID: 33826761
[TBL] [Abstract][Full Text] [Related]
13. Characterization of metastatic urothelial carcinoma via comprehensive genomic profiling of circulating tumor DNA.
Agarwal N; Pal SK; Hahn AW; Nussenzveig RH; Pond GR; Gupta SV; Wang J; Bilen MA; Naik G; Ghatalia P; Hoimes CJ; Gopalakrishnan D; Barata PC; Drakaki A; Faltas BM; Kiedrowski LA; Lanman RB; Nagy RJ; Vogelzang NJ; Boucher KM; Vaishampayan UN; Sonpavde G; Grivas P
Cancer; 2018 May; 124(10):2115-2124. PubMed ID: 29517810
[TBL] [Abstract][Full Text] [Related]
14. Comprehensive Genomic Characterization of Upper Tract Urothelial Carcinoma.
Moss TJ; Qi Y; Xi L; Peng B; Kim TB; Ezzedine NE; Mosqueda ME; Guo CC; Czerniak BA; Ittmann M; Wheeler DA; Lerner SP; Matin SF
Eur Urol; 2017 Oct; 72(4):641-649. PubMed ID: 28601352
[TBL] [Abstract][Full Text] [Related]
15. Circulating tumour DNA in metastatic breast cancer to guide clinical trial enrolment and precision oncology: A cohort study.
Zivanovic Bujak A; Weng CF; Silva MJ; Yeung M; Lo L; Ftouni S; Litchfield C; Ko YA; Kuykhoven K; Van Geelen C; Chandrashekar S; Dawson MA; Loi S; Wong SQ; Dawson SJ
PLoS Med; 2020 Oct; 17(10):e1003363. PubMed ID: 33001984
[TBL] [Abstract][Full Text] [Related]
16. Guardant360 Circulating Tumor DNA Assay Is Concordant with FoundationOne Next-Generation Sequencing in Detecting Actionable Driver Mutations in Anti-EGFR Naive Metastatic Colorectal Cancer.
Gupta R; Othman T; Chen C; Sandhu J; Ouyang C; Fakih M
Oncologist; 2020 Mar; 25(3):235-243. PubMed ID: 32162812
[TBL] [Abstract][Full Text] [Related]
17. Comparative Genomic Profiling of Matched Primary and Metastatic Tumors in Renal Cell Carcinoma.
Becerra MF; Reznik E; Redzematovic A; Tennenbaum DM; Kashan M; Ghanaat M; Casuscelli J; Manley B; Jonsson P; DiNatale RG; Blum KA; Durack JC; Solomon SB; Arcila ME; Bourque C; Socci N; Carlo MI; Lee CH; Voss MH; Feldman DR; Motzer RJ; Coleman JA; Russo P; Cheng EH; Hakimi AA; Hsieh JJ
Eur Urol Focus; 2018 Dec; 4(6):986-994. PubMed ID: 29066084
[TBL] [Abstract][Full Text] [Related]
18. Urinary Molecular Pathology for Patients with Newly Diagnosed Urothelial Bladder Cancer.
Zhang R; Zang J; Xie F; Zhang Y; Wang Y; Jing Y; Zhang Y; Chen Z; Shahatiaili A; Cai MC; Zhao Z; Du P; Jia S; Zhuang G; Chen H
J Urol; 2021 Oct; 206(4):873-884. PubMed ID: 34061567
[TBL] [Abstract][Full Text] [Related]
19. Advanced urothelial carcinoma: next-generation sequencing reveals diverse genomic alterations and targets of therapy.
Ross JS; Wang K; Al-Rohil RN; Nazeer T; Sheehan CE; Otto GA; He J; Palmer G; Yelensky R; Lipson D; Ali S; Balasubramanian S; Curran JA; Garcia L; Mahoney K; Downing SR; Hawryluk M; Miller VA; Stephens PJ
Mod Pathol; 2014 Feb; 27(2):271-80. PubMed ID: 23887298
[TBL] [Abstract][Full Text] [Related]
20. Comprehensive Genomic Profiling of Upper-tract and Bladder Urothelial Carcinoma.
Necchi A; Madison R; Pal SK; Ross JS; Agarwal N; Sonpavde G; Joshi M; Yin M; Miller VA; Grivas P; Chung JH; Ali SM
Eur Urol Focus; 2021 Nov; 7(6):1339-1346. PubMed ID: 32861617
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]